Skip to main content

New insights on low-grade and T-cell lymphoma

The advances in low-grade lymphoma & T-cell lymphoma from the 2008 ASH meeting were presented. These included therapeutic regimens for low grade lymphoma, frontline bendamustine plus rituximab data, radioimmunotherapy consolidation in advanced disease, idiotype vaccine, and other novel therapeutic agents such as next generation anti-CD20 GA101, syk inhibitor Fostamatinib in treatment of low-grade lymphoma. In T-cell lymphoma, updates were discussed on phase II HOVON 69 trial data of combination of alemtuzumab/CHOP, pralatrexate and romidepsin for relapsed/refractory PTCL, L-asparaginase-containing regimen for extranodal NK/T-cell lymphoma.

Author information

Affiliations

Authors

Corresponding author

Correspondence to William Tse.

Rights and permissions

Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Cite this article

Tse, W. New insights on low-grade and T-cell lymphoma. J Hematol Oncol 2, A3 (2009). https://doi.org/10.1186/1756-8722-2-S1-A3

Download citation

Keywords

  • Public Health
  • Lymphoma
  • Cancer Research
  • Therapeutic Agent
  • Advanced Disease